Mid-cap Health Care company Exact Sciences has moved 0.9% so far today on a volume of 64,926, compared to its average of 1,811,400. In contrast, the S&P 500 index moved 0.0%.
Exact Sciences trades -9.46% away from its average analyst target price of $101.96 per share. The 18 analysts following the stock have set target prices ranging from $75.0 to $130.0, and on average have given Exact Sciences a rating of buy.
If you are considering an investment in EXAS, you'll want to know the following:
-
Based on its trailing earnings per share of -2.91, Exact Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -31.7 while the S&P 500 average is 15.97
-
EXAS has a forward P/E ratio of -76.3 based on its forward 12 month price to earnings (EPS) of $-1.21 per share
-
The company has a price to earnings growth (PEG) ratio of -0.48 — a number near or below 1 signifying that Exact Sciences is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 5.43 compared to its sector average of 4.16
-
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
-
Based in Madison, the company has 6,300 full time employees and a market cap of $16.66 Billion.